EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben TM, Kolben T, Zeder-Goess C, Weis F, Gallwas J, Wuerstlein R, Hermelink K, Schmoeckel E, Harbeck N, Mayr D, Mahner S, Jeschke U, Ditsch N.
Semmlinger A, et al. Among authors: schmoeckel e.
BMC Cancer. 2018 Apr 16;18(1):431. doi: 10.1186/s12885-018-4286-9.
BMC Cancer. 2018.
PMID: 29661238
Free PMC article.